Natera introduces prenatal test for detecting inherited conditions
August 8, 2025
The introduction of the test is underpinned by data from the blinded, prospective EXPAND study, which began in 2023.
The introduction of the test is underpinned by data from the blinded, prospective EXPAND study, which began in 2023.
The diagnostic performance of HyCoSy with SF6 microbubbles claims to have been validated by a meta-analysis of 24 trials.
AbbVie has announced that it has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for ELAHERE (mirvetuximab soravtansine) as monotherapy for the treatment of eligible adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
Regulatory milestone supports China’s reproductive health goals by enabling radiation-free, high-accuracy ultrasound imaging to assess fallopian tube patency and uterine abnormalities in women.
In a small new study, a handheld saliva-sampling device successfully detected breast cancer 100% of the time, researchers said.
Scientists at UCSF have found that endometriosis—a painful chronic disease affecting 10% of women that often goes undiagnosed—often occurs alongside conditions like cancer, Crohn’s disease, and migraine.
ORANGE, Calif., July 30, 2025 /PRNewswire/ — Gnosis, a Southern California-based diagnostic lab advancing women’s health through molecular innovation, today announced the national launch of EdenDx, which stands for Early Detection for Endometrial Neoplasia, the first commercially available non-invasive liquid-based cytology test in the United States for early-stage endometrial cancer detection.
In a study conducted in Uganda and published in JAMA Surgery, researchers from Karolinska Institutet evaluated a new surgical method for treating groin hernias in women. The method could become an alternative in resource-limited settings where laparoscopic techniques are not generally available.
ASPIVIX has announced a new partnership with AGHealth to launch Carevix, its MHRA-approved non-traumatic suction cervical stabiliser, in the United Kingdom. The company says this milestone marks a significant advance in UK women’s healthcare, offering a modern and clinically validated alternative to the traditional cervical tenaculum.
Camgenium, a leading medical device software company, has announced that its software product, ‘Reassure Pregnancy’, can improve outcomes for pregnant women at risk of pre-eclampsia through at-home monitoring.